Cagri-GLP1S

Research studies have shown that the two components of Cagri-GLP1S act on separate receptor systems. Researchers have reported that Cagrilintide activates amylin and calcitonin receptors, pathways linked to satiety signaling and gastric emptying rate. GLP-1S, a GLP-1 receptor agonist, has been observed in research to enhance glucose-dependent insulin release and slow gastric emptying. Both peptides carry fatty acid modifications that research has associated with albumin binding and extended duration.

The primary research area for Cagri-GLP1S is energy balance and body weight regulation. In animal models, researchers reported that pairing an amylin analog with a GLP-1 receptor agonist produced larger reductions in food intake and body weight than either peptide alone. Published research suggests the two pathways are complementary, which is the rationale for studying Cagrilintide and GLP-1S together in Cagri-GLP1S.

Beyond body weight, the components of Cagri-GLP1S have been studied in glucose regulation research. In research studies, GLP-1 receptor agonists have been observed to influence glycemic markers and beta cell signaling. Cagrilintide has been examined in rodent studies for effects on meal size and feeding patterns. Cardiovascular and liver fat research are additional areas where the class of peptides in Cagri-GLP1S has been investigated.

The pairing in Cagri-GLP1S is based on both animal model and clinical trial research. Rodent studies first examined an amylin analog together with a GLP-1 receptor agonist. Clinical trials have since evaluated a combination of a long-acting amylin analog with a GLP-1 receptor agonist in human participants, with body weight as a main endpoint. The Cagri-GLP1S research blend itself remains an investigational laboratory material and is not an approved medicine.

Both blends pair Cagrilintide with an incretin class peptide, but they differ in the second component. Cagri-GLP1S uses GLP-1S, a single-target GLP-1 receptor agonist. Cagri-GLP3R uses GLP-3R, a triple agonist of the GLP-1, GIP, and glucagon receptors. Researchers comparing single receptor and multi-receptor incretin signaling alongside amylin receptor activation can choose between Cagri-GLP1S and Cagri-GLP3R on that basis.

Cagri-GLP1S is supplied as a combined lyophilized powder that requires reconstitution. Bacteriostatic water is added slowly down the inside wall of the vial and the contents are swirled gently until the powder dissolves. Cagri-GLP1S should never be shaken, because both peptides carry fatty acid chains and a disulfide bridge that agitation can disturb. Bacteriostatic Water is available on the site as a diluent.

Lyophilized Cagri-GLP1S should be stored at -20 C, protected from light and moisture. After reconstitution, Cagri-GLP1S should be refrigerated at 2 to 8 C, kept away from light, and not put through repeated freeze thaw cycles. Both peptides in the blend were designed for a long duration in research through albumin binding, but that does not replace careful cold storage of prepared solutions.

Yes. Cagri-GLP1S from Biotech Compounds is supplied at 99 percent or greater purity and is third-party tested. A Certificate of Analysis is available on the Cagri-GLP1S product page so researchers can review the purity and identity results for the blend before use. Each lot is tested independently.

Cagri-GLP1S has a combined molecular weight of approximately 10,210.6 g/mol and a combined molecular formula of C481H741N125O143S. These figures represent the two peptides together: Cagrilintide at roughly 4,409 g/mol and GLP-1S making up the remainder. The sulfur atoms reflect the cysteine residues that form the disulfide bridge in Cagrilintide.

No. Cagri-GLP1S from Biotech Compounds is sold strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 years of age or older. Cagri-GLP1S is not a drug or a dietary supplement, and it is not intended for human or animal consumption.